A Checkpoint on Where MS Science Actually Stands

Not every important piece of medical research is a single trial with a dramatic new number attached. Sometimes the most useful thing for patients and doctors alike is a comprehensive review that steps back and asks: given everything we've learned over the past several years, where does the field actually stand? That's what the New England Journal of Medicine published on July 1, 2026, in a major review article titled Advances in Multiple Sclerosis, authored by Dr. Stephen L. Hauser, one of the most prominent researchers in MS immunology.

Multiple sclerosis happens when the immune system attacks myelin, the protective coating around nerve fibers in the brain and spinal cord, causing inflammation and damage that disrupts how nerve signals travel. Over time, that damage can also trigger secondary neurodegeneration, a slower, separate process that's a major driver of long-term disability even after inflammation is controlled. Understanding the difference between these two processes, active inflammation versus underlying neurodegeneration, has become central to how neurologists think about treating MS today.

The review highlights just how far treatment has come for relapsing forms of MS, largely thanks to highly effective disease-modifying therapies, particularly a class of drugs called CD20-targeting monoclonal antibodies, which work by depleting a specific type of immune cell involved in the disease. These drugs have meaningfully changed outcomes for many relapsing MS patients over the past decade, reducing relapse rates and slowing disability progression in ways earlier generations of treatment couldn't.

But the review is equally clear about where the field still falls short. Treatment options for progressive forms of MS, where disability accumulates gradually rather than through distinct relapses, remain limited. The review underscores an urgent, unmet need for therapies that can actually prevent this kind of progression and, ideally, help repair damaged myelin rather than just slowing further damage. That myelin repair goal, sometimes called remyelination, represents one of the biggest open frontiers in MS research right now.

For patients, a review like this doesn't change your treatment tomorrow, but it's a useful gut check on what your neurologist is actually working with. If you have relapsing MS, it reflects genuine, hard-won progress in the tools available to you. If you have a progressive form, it's an honest acknowledgment that the field knows this is where the biggest gap remains, and that meaningful research effort is actively pointed at closing it. Reviews like this one are also worth asking your neurologist about directly, since they can be a useful way to check whether your current treatment plan reflects where the evidence has landed most recently.